Randomiseret klinisk forsøg for at sammenligne oral isotretinoin med standardbehandling hos patienter med moderat akne, hudfarve (ETHNIC)
Randomiseret klinisk forsøg for at sammenligne oral isotretinoin med standardbehandling hos patienter med moderat akne hudfarve: ETNISK undersøgelse
In Dermatology, assessment of people of color remains underrepresented in RCTs (<10%) and guidelines. Acne affects around 9% of the population worldwide and negatively affects quality of life and self-esteem with anxiety, suicidal ideation and physical scarring. Main lesions associate comedons, inflammatory papules and pustules which grading of severity allows decision-making, e.g., topicals in mild acne and isotretinoin in severe acne. In darker skin type patients, i.e., Fitzpatrick phototypes IV-VI, acne-related pigmentation (ARP) occurs in 65% of cases which reflects either per- or post-inflammatory hyperpigmentation. Whatever is the mechanism, ARP (number, size, importance of dyschromia) impacts the quality of life in such patients. In moderate acne, treatment is based on oral antibiotics for 3 months, i.e., doxycycline or lymecycline, with topical treatment like tretinoin targeting comedons (and potentially ARP). However, oral antibiotics first-line were developed in white skin patients only and never showed its efficacy in ARP. Moreover, doxycycline could be associated with new-onset hyperpigmentation in acne patients. Isotretinoin -acting on the sebaceous gland and therefore the most effective drug in acne- is only prescribed after failure of antibiotics according to the guidelines.The main objective: To assess the superiority at M6 of a treatment of moderate facial acne in skin of color patients with oral isotretinoin in first line compared to the current standard of care on the severity of ARP.Multicenter randomized controlled trial - open study. The number of subjects required for the trial = 420
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Thierry Passeron, PhD
- Telefonnummer: +33492036488
- E-mail: passeron.t@chu-nice.fr
Undersøgelse Kontakt Backup
- Navn: Emmanuelle Pradelli
- Telefonnummer: +33492036488
- E-mail: pradelli.e@chu-nice.fr
Studiesteder
-
-
-
Argenteuil, Frankrig
- Rekruttering
- CH D'argenteuil
-
Kontakt:
- Emmanuel MAHE, Ph
- E-mail: emmanuel.mahe@ch-argenteuil.fr
-
Underforsker:
- emmanuel Mahé, Ph
-
Brest, Frankrig
- Rekruttering
- Cabinet Dermatologique Brest 1
-
Kontakt:
- Nicolas Jouan, Ph
- E-mail: nicole.jouan@wanadoo.fr
-
Underforsker:
- Nicole Jouan, Ph
-
Brest, Frankrig
- Rekruttering
- Cabinet Dermatologique Brest 2
-
Kontakt:
- Martine Schollhammer, Ph
- E-mail: Martine.schollhammer@wanadoo.fr
-
Underforsker:
- Martine Schollhammer, Ph
-
Cenon, Frankrig
- Ikke rekrutterer endnu
- Cabinet dermatologique Cenon
-
Kontakt:
- Jean-Michel Amici, Ph
- E-mail: jmamici@gmail.com
-
Underforsker:
- Jean-Michel Amici, Ph
-
Gradignan, Frankrig
- Rekruttering
- Cabinet dermatologique gradignan
-
Kontakt:
- Sandra Ly, Ph
- E-mail: dr.sandra.ly67@gmail.com
-
Underforsker:
- Sandra Ly, Ph
-
La Réunion, Frankrig
- Rekruttering
- CHU de la réunion
-
Kontakt:
- Antoine Bertolotti, PhD
- E-mail: antoine_bertolotti@yahoo.fr
-
Underforsker:
- antoine bertolotti, PhD
-
Paris, Frankrig
- Ikke rekrutterer endnu
- Cabinet dermatologique privé
-
Kontakt:
- Pierre Schneider, Ph
- E-mail: drpierreschneider@gmail.com
-
Underforsker:
- Pierre Schneider, Ph
-
Paris, Frankrig
- Rekruttering
- Ambroise paré
-
Kontakt:
- Tu-Anh Duong, Ph
- E-mail: tu-anh.duong@aphp.fr
-
Underforsker:
- Tu-Anh Duong, Ph
-
Paris, Frankrig
- Rekruttering
- Cabinet dermatologique
-
Ledende efterforsker:
- Christelle Comte
-
Kontakt:
- Christelle Comte
- Telefonnummer: 06.50.72.89.09
- E-mail: Dr.ch.comte@gmail.com
-
Paris, Frankrig
- Rekruttering
- CH Avicenne - APHP
-
Kontakt:
- Gérome Bohelay, Ph
- E-mail: gerome.bohelay@gmail.com
-
Underforsker:
- Gérôme Bohelay, Ph
-
Poitiers, Frankrig
- Rekruttering
- CHU de Poitiers
-
Kontakt:
- Da Hee Pitaud, Ph
- Telefonnummer: 0549444459
- E-mail: Da-hee.pitaud@chu-poitiers.fr
-
Ledende efterforsker:
- Da Hee Pitaud
-
-
Alpes-Maritimes
-
Nice, Alpes-Maritimes, Frankrig, 06200
- Rekruttering
- CHU de Nice - Hôpital de l'Archet
-
Kontakt:
- Thierry Passeron, PhD
- Telefonnummer: +33492036488
- E-mail: passeron.t@chu-nice.fr
-
Ledende efterforsker:
- Thierry Passeron, PhD
-
-
Aquitaine
-
Bordeaux, Aquitaine, Frankrig, 33000
- Rekruttering
- CHU de Bordeaux
-
Kontakt:
- Marie Beylot-Barry, PhD
- E-mail: marie.beylot-barry@chu-bordeaux.fr
-
Underforsker:
- Marie Beylot-Barry, PhD
-
-
Loire-Atlantique
-
Nantes, Loire-Atlantique, Frankrig, 44 000
- Rekruttering
- CHU de Nantes
-
Kontakt:
- Marie Lemoigne, Ph
- E-mail: marie.lemoigne@chu-nantes.fr
-
Underforsker:
- Marie Lemoigne, Ph
-
-
Seine-maritime
-
Rouen, Seine-maritime, Frankrig, 76000
- Rekruttering
- chu de Rouen
-
Kontakt:
- Pascal Joly, PhD
- E-mail: pascal.joly@chu-rouen.fr
-
Underforsker:
- pascal joly, PhD
-
-
Var
-
Sainte-Maxime, Var, Frankrig, 83000
- Rekruttering
- Cabinet de dermatologie St Maxime
-
Kontakt:
- Marc Reverte, Ph
- E-mail: dr.reverte@orange.fr
-
Underforsker:
- Marc Reverte, Ph
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Frankrig, 75000
- Rekruttering
- APHP
-
Kontakt:
- Coralie Lheure, PhD
- E-mail: coralie.lheure@aphp.fr
-
Underforsker:
- Coralie LHEURE, PhD
-
-
-
-
-
Cayenne, Fransk Guyana, 97306
- Rekruttering
- CH de Cayenne 3 Avenue Alexis Blaise, BP6006
-
Kontakt:
- Romain BLAIZOT
- Telefonnummer: 0594397799
- E-mail: romain.blaizot@ch-cayenne.fr
-
Kontakt:
- william faurous
- Telefonnummer: 0594397799
- E-mail: william.faurous <william.faurous@ch-cayenne.fr>
-
Ledende efterforsker:
- Romain Blaizot
-
Fort-de France, Fransk Guyana
- Rekruttering
- Cabinet de dermatologie DERMACLINIC 972
-
Kontakt:
- emilie baubion, Ph
- Telefonnummer: 0767292250
- E-mail: dr.emilie.baubion@gmail.com
-
Ledende efterforsker:
- Emilie Baubion
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Women and men between 13 and 30-year-old
- Skin type IV, V and VI according to Fitzpatrick skin types
- Moderate acne as defined by the French Society of Dermatology recommendations based on ECLA grading https://document.sfdermato.org/groupe/centre-de-preuves/label-recommandations-acne-post-college.pdf)
- Patients must have a cell phone able to take selfies pictures with a minimum definition of 5Mb.
- Signed informed consent
- Affiliation to French social coverage.
Exclusion Criteria:
- Mild and severe acne (ECLA grading : French recommendations) (https://document.sfdermato.org/groupe/centre-de-preuves/label-recommandations-acne-post-college.pdf)
- Past cure of oral isotretinoin
- Past cure of systemic antibiotics for acne in the last 6 months
- Phototype I-III patients
- Abnormal hemogram, liver enzyme, cholesterol, triglycerides at baseline
- Pregnancy: female patient of childbearing potential will undergo a pregnancy test (plasmatic β-hCG)
- Breast-feeding patients
- Refusal of effective contraception for women
- Contra-indications to oral isotretinoin, doxycycline, lymecycline, topical adapalene/tretinoin
- Vulnerable people: adult under guardianship or deprived of freedom
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Drug group
Patients will be followed every month for 6 months in the group isotretinoin. Patients will start at the dose of 0.5 mg/kg/d. If tolerance is poor, the dose could be decrease to 0.25mg/d. After 3 months, following the recommendations the dose could be increase up to 1mg/kg/d depending on the efficacy. |
The dose is usually of 0.5 mg/kg/d. If tolerance is poor, the dose of isotretinoin can be decreased to 0.25 mg/kg/d. After 3 months of treatment, a clinical evaluation is performed. The dose of isotretinoin can be increased up to 1 mg/kg/d depending on the efficacy (ECLA graded as moderated or severe) and tolerance. A total cumulative dose between 120 to 150 mg/kg is recommended. |
|
Aktiv komparator: Doxycycline
Patients will be followed at 3 and 6 months in the group "standard of care". They will be prescribed topical tretinoin or adapalene once daily (every other day if irritation) with doxycycline or lymecycline 100 mg/d. |
Topical retinoic acid (Effederm®) or adapalene cream (Differine®), associated during the 3 first months with doxycycline or lymecycline 100 mg/d. After 3 months, the efficacy is assessed. If acne improved, oral antibiotics are stopped and only the topical treatment is continued. If the ECLA is graded as moderated or severe, isotretinoin should be introduced. |
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Severity of score acne-related pigmentation
Tidsramme: at 6 months
|
To assess the superiority after 6 months of a first line oral isotretinoin treatment of moderate facial acne in skin of color patients compared to the current standard of care on the severity of ARP. |
at 6 months
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Quality of life of patient
Tidsramme: at 6 months
|
Quality of life will be evaluated with the Acne-specific Quality of Life questionnaire (Acne-QoL) |
at 6 months
|
|
Number of adverse events
Tidsramme: during 6 months
|
A special focus on scars will be performed using an Investigator Global Assessment score (0 no scar, 1 mild scarring, 2 moderate, 3 severe) over the study period. |
during 6 months
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Efterforskere
Efterforskere
- Ledende efterforsker: Thierry Passeron, PhD, CHU de Nice, Service de Dermatologie
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Hudsygdomme
- Acneiforme udbrud
- Talgkirtelsygdomme
- Hud- og bindevævssygdomme
- Acne Vulgaris
- Organiske kemikalier
- Retinoider
- Carotenoider
- Polyener
- Alkener
- Kulbrinter, acyklisk
- Kulbrinter
- Cyclohexener
- Cyclohexanes
- Cycloparaffiner
- Kulbrinter, alicyklisk
- Kulbrinter, cyklisk
- Terpenes
- Pigmenter, biologisk
- Biologiske faktorer
- Isotretinoin
- Floderm topical cream
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- 22-APN-02
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .